FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapy

Pharmaceutical Technology

AstraZeneca has secured FDA approval for Imfinzi in combination with BCG induction and maintenance therapy for adults with BCG-nave, high-risk NMIBC.

pharminent June 1, 2026 (Last updated: June 1, 2026)

Pharmaceutical Technology

AstraZeneca has secured FDA approval for Imfinzi in combination with BCG induction and maintenance therapy for adults with BCG-nave, high-risk NMIBC.

Related Stories